These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35906500)

  • 41. QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review.
    Torres-Yaghi Y; Carwin A; Carolan J; Nakano S; Amjad F; Pagan F
    Neuropsychiatr Dis Treat; 2021; 17():3791-3818. PubMed ID: 34992373
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Parkinson's Disease Psychosis and the Marketing of Pimavanserin.
    Daeschler D; Fugh-Berman A
    Int J Soc Determinants Health Health Serv; 2024 Jul; 54(3):272-284. PubMed ID: 38592164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pimavanserin.
    Hunter NS; Anderson KC; Cox A
    Drugs Today (Barc); 2015 Nov; 51(11):645-52. PubMed ID: 26744739
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluating rates of reporting symptoms of Parkinson's disease psychosis: provider versus targeted questionnaire.
    Greger J; Aladeen T; Rainka M; Kale A; Capote H
    Int J Neurosci; 2022 May; 132(5):459-465. PubMed ID: 32910866
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine.
    Dave S; Weintraub D; Aarsland D; Ffytche DH
    Mov Disord Clin Pract; 2020 Jan; 7(1):32-36. PubMed ID: 31970209
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Psychosis in Parkinson's disease].
    Rongve A; Auning E; Ehrt U; Arsland D
    Tidsskr Nor Laegeforen; 2012 Jan; 132(2):155-8. PubMed ID: 22278271
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Scales to evaluate psychosis in Parkinson's disease.
    Goetz CG
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S38-41. PubMed ID: 20083004
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis.
    Tampi RR; Tampi DJ; Young JJ; Balachandran S; Hoq RA; Manikkara G
    World J Psychiatry; 2019 Jun; 9(3):47-54. PubMed ID: 31211112
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study.
    Layton JB; Forns J; Turner ME; Dempsey C; Bartsch JL; Anthony MS; Danysh HE; Ritchey ME; Demos G
    Drugs Real World Outcomes; 2022 Mar; 9(1):9-22. PubMed ID: 34718963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deconstructing psychosis and misperception symptoms in Parkinson's disease.
    Nishio Y; Yokoi K; Uchiyama M; Mamiya Y; Watanabe H; Gang M; Baba T; Takeda A; Hirayama K; Mori E
    J Neurol Neurosurg Psychiatry; 2017 Sep; 88(9):722-729. PubMed ID: 28600444
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review.
    Sellers J; Darby RR; Farooque A; Claassen DO
    Drugs Aging; 2019 Jul; 36(7):647-653. PubMed ID: 30924099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
    Ballard CG; Kreitzman DL; Isaacson S; Liu IY; Norton JC; Demos G; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
    Parkinsonism Relat Disord; 2020 Aug; 77():100-106. PubMed ID: 32712560
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
    Nasrallah HA; Fedora R; Morton R
    Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in Management of Psychosis in Neurodegenerative Diseases.
    Rothenberg KG; Rajaram R
    Curr Treat Options Neurol; 2019 Jan; 21(1):3. PubMed ID: 30673880
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of psychosis in Parkinson's disease: safety considerations.
    Fernandez HH; Trieschmann ME; Friedman JH
    Drug Saf; 2003; 26(9):643-59. PubMed ID: 12814332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators.
    Yasue I; Matsunaga S; Kishi T; Fujita K; Iwata N
    J Alzheimers Dis; 2016; 50(3):733-40. PubMed ID: 26757194
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Frequency and Characteristics of Psychosis in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Chendo I; Silva C; Duarte GS; Prada L; Voon V; Ferreira JJ
    J Parkinsons Dis; 2022; 12(1):85-94. PubMed ID: 34806620
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epidemiology of psychosis in Parkinson's disease.
    Fénelon G; Alves G
    J Neurol Sci; 2010 Feb; 289(1-2):12-7. PubMed ID: 19740486
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Affective Correlates of Psychosis in Parkinson's Disease.
    Factor SA; Scullin MK; Freeman A; Bliwise DL; McDonald WM; Goldstein FC
    Mov Disord Clin Pract; 2017; 4(2):225-230. PubMed ID: 28944257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.